

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/122961 A1

(51) International Patent Classification:

A61K 38/19 (2006.01) A61P 7/00 (2006.01)
A61K 31/4709 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/059012

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

06 December 2024 (06.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/608,007 08 December 2023 (08.12.2023) US

(71) Applicant: **X4 PHARMACEUTICALS, INC.** [US/US];
61 North Beacon Street, 4th Floor, Boston, Massachusetts
02134 (US).

(72) Inventors: **TAVERAS, Art**; c/o X4 Pharmaceuticals, Inc.,
61 North Beacon Street, 4th Floor, BOSTON, Massa-
chusetts 02134 (US). **STEINER, Deborah J.**; c/o X4
Pharmaceuticals, Inc., 61 North Beacon Street, 4th Floor,
BOSTON, Massachusetts 02134 (US). **ARBOT-ENGELS,
Christophe Jean**; c/o X4 Pharmaceuticals, Inc., 61 North
Beacon Street, 4th Floor, BOSTON, Massachusetts 02134
(US).

(74) Agent: **STEVENS, Matthew C.** et al.; c/o Dechert LLP,
One International Place, 40th Floor, 100 Oliver Street,
Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS FOR TREATING NEUTROPENIA

(57) Abstract: The present invention relates to methods of treating patients with neutropenia, such as severe chronic neutropenia, or a related disorder, in which a CXCR4 inhibitor, or a pharmaceutically acceptable salt thereof, is administered to such patients. In some cases, the methods have the advantage of reducing or eliminating side-effects from co-administered agents.

WO 2025/122961 A1